2022 was loaded with US health policy debates and changes, with the reversal of abortion rights and drug pricing reform taking the center stage for much of the year. The Inflation Reduction Act, in addition to climate reform and other key Democratic platform items, will allow the federal government to negotiate Medicare prices for certain high-cost therapeutics.
According to Lecia Bushak, “One provision that would cap the price of insulin at $35 per month didn't make it into the final legislative package, for example, and insulin prices have remained a hot topic throughout 2022. During Elon Musk's messy Twitter takeover, a fake Eli Lilly tweet announcing it would make insulin free poked at the issue, went viral and cost the company billions in market cap. More recently, entrepreneur Mark Cuban has also vowed that his Mark Cuban Cost Plus Drug company would eventually begin offering low-cost insulin.”
To read more, click here.
(Source: MM+M, December 27th, 2022)